



QIArearch[®] SARS-CoV-2 Antigen Test

Quick Reference Guide



The QIArearch[®] SARS-CoV-2 Antigen Test is a rapid, digital lateral flow diagnostic assay, using nanoparticle fluorescence, intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal (NP) and anterior nasal (AN) swab specimens collected in Copan[®] Diagnostic Universal Transport Media (UTM-RT™) from individuals who are suspected of COVID-19 by their healthcare provider within the first six days of symptom onset. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate and high complexity tests.

The QIArearch[®] SARS-CoV-2 Antigen Test does not differentiate between SARS-CoV or SARS-CoV-2 viruses.

Results are for the identification of SARS-CoV-2 nucleocapsid protein antigen. Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. Negative results should be treated as presumptive, and confirmation with a molecular assay, if necessary, for patient management may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient's recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19.

The QIArearch SARS-CoV-2 Antigen Test is only to be used with the QIArearch eHub.

The QIArearch SARS-CoV-2 Antigen Test is intended for use by clinical laboratory personnel specifically instructed on in vitro diagnostic procedures.

The QIArearch SARS-CoV-2 Antigen Test has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.

This QIArearch SARS-CoV-2 Antigen Test has been authorized only for the detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal and nasal swab specimens, not for any other viruses or pathogens, and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3 (b)(1), unless the declaration is terminated or authorization is revoked sooner.

Due to the risk of false-positive results, confirmation of positive results should be considered using a different molecular assay. Please study the QIArearch SARS-CoV-2 Antigen Test Instructions for Use (Handbook) thoroughly before referring to this Quick Reference Guide. This Quick Reference Guide is not intended as an exhaustive instructional document.

IVD

RX ONLY

For use under Emergency Use Authorization (EUA) only


REF 646533

Test Kit Contents (REF 646533)

60 x QIArearch SARS-CoV-2 Antigen eSticks

60 x QIArearch SARS-CoV-2 Antigen Processing Tubes

2 x 10ml QIArearch SARS-CoV-2 Antigen Diluent Buffer




Additional Components Required


QIArearch eHub

Adjustable Volume Pipettes + tips
Volume/s required: 100µl, 400µl

Swab and transport media (Copan UTM[®])
Minimum collection volume 1ml



Pre-analytical Steps




Nasal swab

Patient sample collected through Nasal or Nasopharyngeal

swab. For Nasal and Nasopharyngeal swab collection, follow swab manufacturer instructions and CDC guidelines.



Nasopharyngeal swab




Patent sample stored in viral transport media (Copan UTM) to

Manufacturer's instructions. Please refer to IFU for further details.

QIArearch eHub Setup



Remove QIArearch eHub from its packaging.



Remove the dust cover from the front of the QIArearch eHub.



Power USB

Connect the eHub to power via USB (wall plug or PC). Press the power button to turn on the QIArearch eHub.

NB: Refer to QIArearch eHub User Manual for a complete guide to device operation and troubleshooting.

www.qiagen.com
800-344-3631

Technical support: techservice-na@qiagen.com




Sample to Insight

Test Procedure

Note: Refer to the *QIArearch SARS-CoV-2 Antigen Test Instructions for Use* for Warnings and Precautions, Directions for Use, Results, Analysis and Test Interpretation, Technical Information, and Troubleshooting. For required positive and negative control testing associated with the QIArearch SARS-CoV-2 Antigen Test, use the QIArearch SARS-CoV-2 Antigen Controls product; this product is sold separately and is available from QIAGEN (Catalog Number 646030). External controls should be run as outlined in the procedure for testing the samples. Positive and negative controls are required to be tested each time a new lot is used, when a new operator performs the test, or when the test is run in a new room/laboratory, etc., as a good laboratory practice to confirm the test procedure and to verify proper test performance.


- 1 Ensure that the QIArearch eHub is turned on, then insert the QIArearch Processing Tube and eStick.




Record patient information

eStick must be used within 1hr of unwrapping


- 2 Transfer 100 µl of QIArearch Diluent Buffer solution into the QIArearch Processing Tube.




- 3 Draw 400 µl of patient sample from transport media (Copan UTM). Refer to IFU for further detail.



- 4 Transfer the sample to the QIArearch Processing Tube.




- 5 Mix the contents at least 4 times to mix the sample in the QIArearch Processing Tube.




At least 4 times

- 6 Transfer 100 µl from the QIArearch Processing Tube to the eStick.



- 7 The test will run automatically and display a result within 2–15 minutes.



Wait for result before removing the eStick

Disclaimer:

- QIArearch SARS-CoV-2 Antigen results should not be used to diagnose or exclude acute infection. Results are not intended to be used as the sole basis for patient management decisions. Test results should be interpreted in conjunction with clinical observations, patient history, epidemiological information, and other laboratory findings.